Home > Sobre nosotros > Publicaciones de prensa > Archivos

Archivos

• 05-12-07

  ReGen Biologics Introduces New Brand Name and Websites

• 21-11-07

  ReGen Biologics Enters New Markets in Poland and South Africa

• 24-08-07

  ReGen Biologics Receives NSE Letter from FDA, Proceeding with Next Steps to Gain U.S. Market Clearance

• 08-07-07

  ReGen Biologics to Exhibit at 2007 AOSSM Annual Meeting

• 25-06-07

  ReGen Biologics Responds to Request for Additional Information on Pending 510(k)

• 24-05-07

  ReGen Biologics to Launch Lateral CMIâ„¢ at 6th Biennial ISAKOS Congress

• 25-04-07

  ReGen Biologics Participates in 2007 AANA Annual Meeting

• 04-04-07

  ReGen Biologics Closes $2.7 Million Private Placement

• 05-03-07

  ReGen Biologics Closes Additional $3 Million Private Placement

• 25-02-07

  ReGen Biologics Data Presented in San Diego

• 05-02-07

  ReGen Biologics to Present at First Albany’s Second Annual Orthopedics Conference on February 13, 2007

• 04-02-07

  ReGen Biologics Participates in 2007 AAOS Annual Meeting

• 03-12-06

  ReGen Biologics Completes Approximately $7 Million Private Placement

• 12-11-06

  ReGen Biologics Announces Results of FDA Appeal

• 06-11-06

  ReGen Biologics Announces New CMI Clinical Results

• 06-09-06

  ReGen Biologics Provides Update on 510(k) Submission

• 19-06-06

  ReGen Biologics Tissue Growth Data Presented

• 30-05-06

  Regen Biologics CMIâ„¢ Topic of Symposium

• 15-05-06

  ReGen Biologics Hosts Annual Shareholder Meeting

• 07-05-06

  ReGen Biologics Meniscus Data To Be Presented

• 02-05-06

  Recent Article Validates Tools Used by ReGen Biologics to Measure Meniscus Performance

• 30-04-06

  ReGen Biologics Reports First Bilateral CMIâ„¢ Procedure

• 27-04-06

  ReGen Biologics Provides Update on 510(K) Regulatory Submission

• 26-02-06

  CMIâ„¢ Labeling Expanded in Europe to Include Lateral Use

• 29-01-06

  ReGen Biologics Meniscus Data Featured in Scientific Meetings

• 03-01-06

  ReGen Biologics Announces 510(k) Regulatory Submission in the U.S.

• 20-11-05

  ReGen Biologics Completes Distribution Coverage in Spain with Exclusive Agreement

• 15-11-05

  Regen Biologics Signs Exclusive Distribution Agreement for Spain

• 13-11-05

  International Symposium Features Latest CMIâ„¢ Data

• 30-10-05

  ReGen Biologics Signs Exclusive Distribution Agreement for Italy

• 29-08-05

  ReGen Biologics Launches European Website

• 22-08-05

  FDA Follows-up on Form 483 Notice of Inspectional Observations with Warning Letter

• 14-07-05

  ReGen Biologics Completes $11.8 Million Private Placement

• 25-05-05

  ReGen Biologics AG to Host June 6, 2005 Evening Event at EFORT Congress in Lisbon for Surgeons Interested in ReGen® CMI

• 24-05-05

  ReGen Biologics Surgeons Successfully Complete Lateral CMIâ„¢Surgeries

• 24-05-05

  ReGen Biologics To Present at the Pacific Growth Equities Life Science Conference in San Francisco on June 6, 2005

• 16-05-05

  ReGen Biologics Announces Publication of Five Year Data from CMI Feasibility Study in Arthroscopy

• 17-03-05

  ReGen Biologics Reports Select Operating Results for 2004

• 06-03-05

  ReGen Regains Exclusive Worldwide Distribution Rights for its CMI

• 06-10-04

  ReGen Biologics to Present at the HealthPoint Capital New York Biomaterials Summit

• 25-07-04

  ReGen Biologics Begins Modular FDA Pre-Market Approval Submission for CMI Product

• 09-06-04

  William R. Timken, Former Vice Chairman of Hambrecht & Quist, Named to ReGen Biologics Board of Directors

• 20-04-04

  ReGen Biologics Completes Private Placement of Common Stock for Gross Proceeds of Approximately $10.3 Million

• 26-02-04

  ReGen Biologics Continues Advance Towards FDA Submission with the Selection of Key FDA Consulting Firm

• 30-11-03

  ReGen Biologics to Present at Harris Nesbitt Gerard Focus on Healthcare Conference December 11 in New York City

• 27-10-03

  ReGen Biologics Retains Cameron Associates as Investor Relations Advisor

• 15-10-03

  ReGen Biologics To Present At Rodman & Renshaw Techvest Healthcare Conference

• 30-09-03

  ReGen Biologics Finalizes Private Placement Totaling $10 Million

• 22-08-03

  ReGen Biologics Completes Private Placement

• 18-05-03

  ReGen Biologics Appoints Abhi Acharya, Ph.D. to Board of Directors

• 18-03-03

  ReGen Biologics Launches New Website

• 05-01-03

  ReGen Biologics Announces 2002 Accomplishments

• 01-12-02

  ReGen Biologics Filed U.S. Patent Application for Membrane Enforced Implant

• 21-11-02

  ReGen Biologics CEO Interview at Ceocast.com

• 19-11-02

  ReGen Announces Completion of CMI Clinical Trial Surgeries

• 18-11-02

  Aros Corporation Announces Name and Ticker Change

• 21-10-02

  German Magazine, Stern, Interviews ReGen Biologics’ Director, Dr. Richard Steadman and Highlights ReGen’s Groundbreaking Meniscal Repair Procedure

• 29-09-02

  ReGen Obtains Approval in Australia

• 25-09-02

  ReGen Biologics Announces the Completion of U.S. Clinical Trial Enrollments

• 22-09-02

  Aros To Postpone Annual Meeting of Stockholders

• 18-07-02

  ReGen CMI Featured At 3rd International Heidelberg Orthopedic Symposium

• 24-06-02

  Aros Completes Acquisition of ReGen Biologics

• 04-07-00

  ReGen Biologics CMI Recognized With GOTS-Beiersdorf Orthopaedic Research Award

• 10-05-00

  ReGen Biologics Receives Financing From Sulzer Medica

• 16-04-00

  ReGen Biologics Announces Licensing Agreement For The SharpShooter® Tissue Repair System for Meniscus Repair

• 04-04-00

  ReGen Biologics Commences European Market Launch of CMI Through Sulzer Medica

• 21-02-00

  ReGen Biologics Receives CE Marking for CMI